 <!DOCTYPE html>
<html style="height:100%;" lang="en-US">
<head>
<title>Current Research - OHRLA</title>
<link rel="stylesheet" href="styles.css">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css">
<meta charset="ISO-8859-1">
<meta name="description" content="Cancer Research">
<meta name="keywords" content="Head and Neck,Cancer,Surgeon,Edmonton,Alberta,Canada">
<meta name="author" content="Cameron Lindsay">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<style>
@charset "utf-8";

@media screen and (max-width: 600px) {
        .column.side, .column.middle {
		width: 100%;
	}
}
</style>
</head>
<body>

<!-- Title stuff -->
<div class="header">
<img src="logo.png" alt="logo goes here" style="float:left;width=317px;height=109px;">
<h1 title="Otolaryngology - Head and Neck Surgery Research Laboratory of Alberta"><------OHRLA integrated into logo on left</h1>
</div>

<!-- Nav menu -->

<nav>
<ul>
<li><a href="home.htm">Home</a></li>
<li><a href="news.htm">News</a></li>

<li class="dropdown">
	<a class="active" href="rsch.htm" class="dropbtn">Research</a>
	<div class="dropdown-content">
		<a class="active" href="currentrsch.htm">Current Reseach</a>
		<a href="pastrsch.htm">Publications</a>
</div></li>

<li class="dropdown">
	<a href="about.htm" class="dropbtn">About Us</a>
	<div class="dropdown-content">
		<a href="mission.htm">Mission</a>
		<a href="team.htm">OHRLA Team</a>
		<a href="careers.htm">Careers</a>
		<a href="contact.htm">Contact</a>
</div></li>

<li style="float:right"><a class="active" href="https://fundrazr.com/unmasked.uhf?fb_ref=share__fb_3btxKMJJNCk3btxKMJJNCk&fbclid=IwAR0UhDB2iHKrhnuh-XT49E7D5M2lv_X0SazYgoAF4TeYa8w7d5HRuYO_J0Q" target="_blank">Donate</a></li>
</ul>
</nav>


<!-- Main Content -->

<div class="parallax1">
	<div class="container">
		<div class="imgtitle">
		<h1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current Research</h1>
		</div>
	</div>
</div>

<div class="row">
	<div class="column side">
	<p></p>
	</div>

<div class="column middle">
	<div class="textbox">
<p><h3>Overview</h3>
<p>
Head and neck squamous cell carcinoma (HNSCC) is
the fifth most common malignancy worldwide [1], with the
incidence of oropharyngeal squamous cell carcinoma
(OPSCC), a subsite of HNSCC, rapidly increasing in
North America [2]. Although traditional risk factors for
HNSCC include smoking and alcohol use, the rising incidence
of OPSCC has been attributed largely to the Human
Papillomavirus (HPV), more specifically serotypes HPV16 and HPV18 [3–6].
HPV infection is carcinogenic
through expression of oncogenic proteins E6 and E7
which cause multiple genetic and metabolic effects
within the cell, the most important of which is degradation
of tumor suppressor genes including p53 and Rb
[18]. By a separate pathway, this results in downstream
overexpression of p16.<br><br>

<img src="CDKN2A.png" alt="Pathways Figure" class="center" style="width:75%;height:75%;padding: 10px;border:solid 2px;"><br><br></p>
	</div>
<br>
	<div class="textbox">
<h4>Project 1. Droplet digital PCR as a unique method of determining HPV status</h4>
<p>Determining HPV positivity is of critical importance in the diagnosis and management of
OPSCC, as HPV positive tumours have unique pathologic
and clinical characteristics that have implications for prognosis
and treatment decisions [3, 7–10].
The current gold standard for determining HPV status in
OPSCC is demonstration of oncogenic HPV DNA in
fresh tissue using real-time quantitative polymerase
chain reaction (RT-qPCR) [1, 11, 12]. Due to the high
cost and specialized equipment required for this method,
most centers have adopted p16 immunohistochemistry
(p16 IHC) as the preferred method of oncogenic HPV
detection, which has become the clinical standard. [13–17]
However, p16 IHC is an imperfect surrogate marker for
HPV-associated OPSCC. Because p16 overexpression can
occur through HPV-independent pathways, p16 IHC
can lead to false positives, which could result in erroneous
de-intensification of treatment. Although RT-PCR
of E6 and E7 can circumvent the limitations of p16
IHC, it also requires adequate nucleic acid sample
generally only attainable from tissue biopsy.
Droplet digital polymerase chain reaction (ddPCR) is a
relatively novel technique with potential applications for
HPV detection in OPSCC. ddPCR is the most accurate
and sensitive mode of measuring target nucleic acids
quantitatively in the available literature [19]. ddPCR
involves partitioning a single nucleic acid sample in up to
20,000 discrete water-in-oil droplets and performing PCR
analysis on each droplet independently, with the results
reported digitally and quantitatively. This technique quantifies
the absolute amount of target nucleic acid present
with greater precision and reproducibility than RT-qPCR
[20–23]. ddPCR has been used to quantify gene expression
with extremely low copy number [24, 25], and has
demonstrated better diagnostic performance in biomarker
analysis than other molecular techniques. [22, 26, 27] One
study made use of ddPCR for detection of oncogenic E6/
E7 mRNA in fresh tissue OPSCC specimens and found
100% sensitivity compared to p16 IHC using target RNA
20–50 times lower than reported for RT-qPCR [28].
Because of the accuracy and ultra-sensitivity of ddPCR
for identification of oncogenic HPV E6/E7 mRNA, we
hypothesized that ddPCR can be used for detection of
oncogenic HPV in OPSCC using oral/oropharyngeal
swabs as opposed to fresh tissue. The ability to detect
oncogenic HPV without a tissue biopsy would have
important implications for diagnosis, post-treatment
surveillance, and screening of patients with OPSCC.
The purpose of this study was to validate the use of a
novel minimally-invasive assay for detection of oncogenic
HPV based on oral/oropharyngeal swabs using
ddPCR. Our secondary objectives were to compare the
accuracy of ddPCR swabs to fresh tissue p16 IHC, and
to report the cost of ddPCR.</p>

<h4>Publication/s:</h4>
<p><ul style="font-size:14px;list-style-type:none;margin: 0;padding: 0px;">
<li>Isaac, A., Kostiuk, M., Zhang, H., Lindsay, C., Makki, F., O’Connell, D. A., ... & Biron, V. L.
 Ultrasensitive detection of oncogenic human papillomavirus in oropharyngeal tissue swabs. Journal of Otolaryngology-Head & Neck Surgery. 2017. 46(1), 5.</li><br>
<li>Biron VL, Kostiuk M, Isaac A, et al. Detection of human papillomavirus type
16 in oropharyngeal squamous cell carcinoma using droplet digital
polymerase chain reaction. Cancer. 2016. doi:10.1002/cncr.29976.</li></ul></p>

<h4>Future Goals:</h4>
<ul style="font-size:14px">
<li>Increase size and scope of patients recruited</li>
<li>Include patients with cervical cancers in recruitment</li>
</ul><br><br>
	</div>
<br>
	<div class="textbox">
<h4>Project 2. Curcumin and Metformin as potential chemotherapeutic modalities:</h4>
<p>The standard practices for the treatment of HNSCC involves combination surgery, chemo- and radiotherapy. Unfortunately standard practices report modest response rates and poor quality of life post-treatment [29, 30].
 However, HPV-positive OPSCC clinical outcomes are significantly better than their HPV-negative counterparts, as tumors display an increased response to surgical intervention, chemotherapeutics, and radiotherapies [31-34]. 
Due to the severe side effects currently encountered by modern chemotherapeutics, novel agents that are well-tolerated are in high demand. 
Metformin is one such agent that is currently a widely-used, inexpensive, and well-tolerated first-line oral agent utilized in the treatment of type 2 diabetes mellitus via inhibition of gluconeogenesis [35].
 The primary mechanism of gluconeogenesis inhibition by metformin and other biguanides is believed to be through the activation of the LKB1-AMPK pathway [36].
 A result of this LKB1-AMPK pathway activation is the inhibition of the mammmalian Target of Rapamycin (mTOR), a known biomarker for a subset of insulin-stimulated cancer cells [36-38].
 It is surmised that inhibition of mTOR is one of the primary methods of the chemopreventitive properties of metformin treatment observed in several cancers (Summarized in [39, 40]).
 Metformin’s chemopreventive activity has also been observed in HNSCC. 
A 2015 study, 66,600 diabetic patients, being treated with metformin or without metformin, observed a 34% lower incidence of head and neck cancer in patients taking metformin [41].  
The affects of treatment with metformin included the induction of apoptosis, reduction of cell proliferation, tumor size and growth, as well as cisplatin sensitization both in vitro and in vivo [42-45]. 
Curcumin is another well-tolerated agent quickly gaining attention for its medicinal properties. 
Curcumin is the yellow polyphenol found in the Asian spice tumeric and has been found to have anti-oxidant, anti-inflammatory, and anti-tumorigenic properties [46]. 
A comprehensive review by Kunnumakkara and collegues details several cell signalling pathways that are suggested to be implicated in curcumin’s anti-cancer properties [47]. 
Included in his list are NF-ĸB, STAT3, PI3K/AKT/mTOR, EGFR, Nrf2, Notch 1, WT1, AP-1, HIF-1, Wnt/β-catenin, and EGR-1 signalling pathways. 
Additionally, they report on curcumin’s interactions with several non-coding RNAs and epigenetic regulators. 
Combined treatment with curcumin and various anticancer drugs, such as 5-FU and cisplatin, may overcome drug resistance resulting in increased anticancer efficacy and reduced host toxicity in vitro and in vivo [48-50].
 When utilized in HNSCC, anti-carcinogenic properties of curcumin also include induction of apoptosis, cell cycle arrest, radiosensitivity, and chemotherapy sensitization [51].
  Combination treatment with metformin and curcumin has also shown enhanced chemopreventative properties in HNSCC in vitro and in vivo [52]. 
To date, there does not appear to be any studies comparing the differences between HPV-positive and HPV-negative OPSCC following treatment combining both metformin and curcumin.</p>

<h4>Future Goals:</h4>
<ul style="font-size:14px">
<li>Observe the overall efficacy of these agents in interefering with overall cell viability and proliferation</li>
<li>Impact on common biomarkers frequently associated with OPSCC</li>
</ul><br><br>  
	</div>
<br>
	<div class="textbox">
<h4>References</h4>
<p style="font size:10px;">
1. Hayes DN, Van Waes C, Seiwert TY. Genetic landscape of human
papillomavirus-associated head and neck cancer and comparison to
tobacco-related tumors. J Clin Oncol. 2015;33(29):3227–34. doi:10.1200/
JCO.2015.62.1086.<br>
2. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and
rising oropharyngeal cancer incidence in the United States. J Clin Oncol.
2011;29(32):4294–301. doi:10.1200/JCO.2011.36.4596.<br>
3. Lowy DR, Munger K. Prognostic implications of HPV in oropharyngeal
cancer. N Engl J Med. 2010;363(1):82–4. doi:10.1056/NEJMe1003607.<br>
4. Marklund L, Hammarstedt L. Impact of HPV in oropharyngeal cancer.
J Oncol. 2011. doi:10.1155/2011/509036.<br>
5. Osazuwa-Peters N. Human papillomavirus (HPV), HPV-associated oropharyngeal
cancer, and HPV vaccine in the United States-Do we need a broader vaccine
policy? Vaccine. 2013;31:5500–5. doi:10.1016/j.vaccine.2013.09.031.<br>
6. Shaw R, Robinson M. The increasing clinical relevance of human
papillomavirus type 16 (HPV-16) infection in oropharyngeal cancer.
Br J Oral Maxillofac Surg. 2011;49(6):423–9. doi:10.1016/j.bjoms.2010.06.023.<br>
7. Biron VL, Mohamed A, Hendzel MJ, Underhill DA, Seikaly H. Epigenetic
differences between human papillomavirus-positive and -negative
oropharyngeal squamous cell carcinomas. J Otolaryngol - Head Neck Surg.
2012;41(SUPPL. 1). doi:10.2310/7070.2011.110087.<br>
8. Seikaly H, Biron VL, Zhang H, et al. Role of primary surgery in the treatment of
advanced oropharyngeal cancer. Head Neck. 2015. doi:10.1002/hed.24042.<br>
9. Xu CC, Biron VL, Puttagunta L, Seikaly H. HPV Status And Second Primary
Tumours In Oropharyngeal Squamous Cell Carcinoma. J Otolaryngol - Head
Neck Surg. 2013;42. Doi:10.1186/1916-0216-42-36.<br>
10. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of
patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35. doi:
10.1056/NEJMoa0912217.<br>
11. Nishat R, Behura SS, Ramachandra S, Kumar H, Bandyopadhyay A. Human
papilloma virus (HPV) induced head & neck squamous cell carcinoma: a
comprehensive retrospect. J Clin Diagn Res. 2015;9(6):ZE01–4. doi:10.7860/
JCDR/2015/13948.6056.<br>
12. Walline HM, Komarck C, McHugh JB, et al. High-risk human
papillomavirus detection in oropharyngeal, nasopharyngeal, and o
ral cavity cancers. JAMA Otolaryngol Neck Surg. 2013;139(12):1320.
doi:10.1001/jamaoto.2013.5460.<br>
13. Lewis JS, Thorstad WL, Chernock RD, et al. p16 positive oropharyngeal
squamous cell carcinoma:an entity with a favorable prognosis regardless of
tumor HPV status. Am J Surg Pathol. 2010;34(8):1088–96. doi:10.1097/PAS.
0b013e3181e84652.<br>
14. Thomas J, Primeaux T. Is p16 immunohistochemistry a more cost-effective
method for identification of human papilloma virus-associated head and
neck squamous cell carcinoma? Ann Diagn Pathol. 2012;16(2):91–9. doi:10.
1016/j.anndiagpath.2011.09.002.<br>
15. Oguejiofor KK, Hall JS, Mani N, et al. The prognostic significance of the
biomarker p16 in oropharyngeal squamous cell carcinoma. Clin Oncol (R
Coll Radiol). 2013;25(11):630–8. doi:10.1016/j.clon.2013.07.003.<br>
16. Lewis JS. p16 immunohistochemistry as a standalone test for risk
stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol.
2012;6 Suppl 1:75–82. doi:10.1007/s12105-012-0369-0.<br>
17. El-Naggar AK, Westra WH. p16 expression as a surrogate marker for HPVrelated
oropharyngeal carcinoma: a guide for interpretative relevance and
consistency. Head Neck. 2012;34(4):459–61. doi:10.1002/hed.21974.<br>
18. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to
transformation. Nat Rev Cancer. 2010;10(8):550–60. doi:10.1038/nrc2886.<br>
19. Albano F, Zagaria A, Anelli L, et al. Absolute quantification of the
pretreatment PML-RARA transcript defines the relapse risk in acute
promyelocytic leukemia. Oncotarget. 2015;6(15):13269–77. http://www.
scopus.com/inward/record.url?eid=2-s2.0-84931038270&partnerID=tZOtx3y1.<br>
20. McDermott GP, Do D, Litterst CM, et al. Multiplexed target detection using
DNA-binding dye chemistry in droplet digital PCR. Anal Chem. 2013;85(23):
11619–27. doi:10.1021/ac403061n.<br>
21. Hindson CM, Chevillet JR, Briggs HA, et al. Absolute quantification by
droplet digital PCR versus analog real-time PCR. Nat Methods. 2013;10(10):
1003–5. doi:10.1038/nmeth.2633.<br>
22. Fontanelli G, Barate C, Ciabatti E, et al. Real-Time PCR and Droplet Digital
PCR: two techniques for detection of the JAK2 mutation in Philadelphianegative
chronic myeloproliferative neoplasms. Int J Lab Hematol. 2015.
doi:10.1111/ijlh.12404.<br>
23. Idris S, Lindsay C, Kostiuk M, et al. Investigation of EZH2 pathways for novel
epigenetic treatment strategies in oropharyngeal cancer. J Otolaryngol -
Head Neck Surg. 2016;45(1):54. doi:10.1186/s40463-016-0168-9.<br>
24. Watanabe M, Kawaguchi T, Isa SI, et al. Ultra-sensitive detection of the
pretreatment EGFR T790M mutation in non-small cell lung cancer patients
with an EGFR-activating mutation using droplet digital PCR. Clin Cancer Res.
2015;21(15):3552–60. doi:10.1158/1078-0432.CCR-14-2151.<br>
25. Yu M, Carter KT, Makar KW, et al. MethyLight droplet digital PCR for
detection and absolute quantification of infrequently methylated alleles.
Epigenetics. 2015;10(9):803–9. doi:10.1080/15592294.2015.1068490.<br>
26. Wang P, Jing F, Li G, et al. Absolute quantification of lung cancer related
microRNA by droplet digital PCR. Biosens Bioelectron. 2015;74:836–42.
doi:10.1016/j.bios.2015.07.048.<br>
27. Wang Q, Yang X, He Y, et al. Droplet digital PCR for absolute quantification
of EML4-ALK gene rearrangement in lung adenocarcinoma. J Mol Diagn.
2015;17(5):515–20. doi:10.1016/j.jmoldx.2015.04.002.<br>
28. Biron VL, Kostiuk M, Isaac A, et al. Detection of human papillomavirus type
16 in oropharyngeal squamous cell carcinoma using droplet digital
polymerase chain reaction. Cancer. 2016. doi:10.1002/cncr.29976.<br>
29. Colevas, A.D., et al., NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. J Natl Compr Canc Netw, 2018. 16(5): p. 479-490.<br>
30. Hoxbroe Michaelsen, S., et al., Quality of life in survivors of oropharyngeal cancer: A systematic review and meta-analysis of 1366 patients. Eur J Cancer, 2017. 78: p. 91-102.<br>
31. Fakhry, C., et al., Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst, 2008. 100(4): p. 261-9.<br>
32. Clark, J., et al., Correlation of PET-CT nodal SUVmax with p16 positivity in oropharyngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg, 2015. 44: p. 37.<br>
33. Ang, K.K. and E.M. Sturgis, Human Papillomavirus as a Marker of the Natural History and Response to Therapy of Head and Neck Squamous Cell Carcinoma. Seminars in Radiation Oncology, 2012. 22(2): p. 128-142.<br>
34. Xu, C.C., et al., HPV status and second primary tumours in oropharyngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg, 2013. 42: p. 36.<br>
35. Rhee, M.K., et al., Many Americans have pre-diabetes and should be considered for metformin therapy. Diabetes Care, 2010. 33(1): p. 49-54.<br>
36. Pollak, M., Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila), 2010. 3(9): p. 1060-5.<br>
37. Pollak, M., Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer, 2008. 8(12): p. 915-28.<br>
38. Kourelis, T.V. and R.D. Siegel, Metformin and cancer: new applications for an old drug. Med Oncol, 2012. 29(2): p. 1314-27.<br>
39. Quinn, B.J., et al., Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab, 2013. 24(9): p. 469-80.<br>
40. Kasznicki, J., A. Sliwinska, and J. Drzewoski, Metformin in cancer prevention and therapy. Ann Transl Med, 2014. 2(6): p. 57.<br>
41. Yen, Y.C., et al., Effect of metformin on the incidence of head and neck cancer in diabetics. Head Neck, 2015. 37(9): p. 1268-73.<br>
42. Vitale-Cross, L., et al., Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev Res (Phila), 2012. 5(4): p. 562-73.<br>
43. Sikka, A., et al., Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle, 2012. 11(7): p. 1374-82.<br>
44. Qi, X., et al., Metformin sensitizes the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-kappaB/HIF-1alpha signal axis. Sci Rep, 2016. 6: p. 35788.<br>
45. Rego, D.F., et al., Anti-tumor effects of metformin on head and neck carcinoma cell lines: A systematic review. Oncol Lett, 2017. 13(2): p. 554-566.<br>
46. Joe, B., M. Vijaykumar, and B.R. Lokesh, Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr, 2004. 44(2): p. 97-111.<br>
47. Kunnumakkara, A.B., et al., Curcumin mediates anticancer effects by modulating multiple cell signaling pathways. Clin Sci (Lond), 2017. 131(15): p. 1781-1799.<br>
48. Wei, Y., et al., The combination of curcumin and 5-fluorouracil in cancer therapy. Arch Pharm Res, 2018. 41(1): p. 1-13.<br>
49. Pandey, A., et al., Berberine and Curcumin Target Survivin and STAT3 in Gastric Cancer Cells and Synergize Actions of Standard Chemotherapeutic 5-Fluorouracil. Nutr Cancer, 2015. 67(8): p. 1293-304.<br>
50. Fetoni, A.R., et al., Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling. Br J Cancer, 2015. 113(10): p. 1434-44.<br>
51. Borges, G.A., et al., In vivo and in vitro effects of curcumin on head and neck carcinoma: a systematic review. J Oral Pathol Med, 2017. 46(1): p. 3-20.<br>
52. Siddappa, G., et al., Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells. Mol Carcinog, 2017. 56(11): p. 2446-2460.<br>
</p>
	</div>

</div>

<div class="column side">
<p></p>
</div>
</div>


<!-- Footer-->
<br><br>
<footer>
<div class="row">
	<div class="column footer">
	<p><h4>OHRLA LOGO</h4>OHRLA seeks to research and develop novel modalities in the diagnosis, treatment, and prevention of head and neck cancers.</p>
	</div>
	<div class="column footer2">
	</div>
	<div class="column footer">
	<p><h4>CONTACT</h4>
	3-025 Li Ka Shing Centre for Health Research Innovation<br>
	University of Alberta Hospital<br>
	8602 112 Street<br>
	Edmonton, AB, Canada<br>
	T6G 2E1<br><br>
	Phone:<br>
	Email:<br>
	URL:</p></div>

	<div class="column footer">
	<p><h4>QUICK LINKS</h4></p>
	<ul style="list-style-type:none;margin: 0;padding: 0px;">
	<li><a href="home.htm">Home</a></li>
	<li><a href="news.htm">News</a><li>
	<li><a href="currentrsch.htm">Current Reseach</a></li>
	<li><a href="pastrsch.htm">Publications</a></li>
	<li><a href="mission.htm">Mission</a><li>
	<li><a href="team.htm">OHRLA Team</a></li>
	<li><a href="careers.htm">Careers</a></li>
	<li><a href="contact.htm">Contact</a></li></ul>
	<a href="https://www.facebook.com/zuck" class="fa fa-facebook"></a>
	<a href="#" class="fa fa-twitter"></a>
	<a href="#" class="fa fa-linkedin"></a></div>
</div>
</footer>
</body>
</html> 